Abstract
The objective of this work was to discover a novel, long-acting muscarinic M(3) antagonist for the inhaled treatment of chronic obstructive pulmonary disease (COPD), with a potentially improved risk-benefit profile compared with current antimuscarinic agents. A series of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters were synthesized and evaluated. On the basis of its overall profile, (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) emerged as a candidate for once-daily maintenance treatment of COPD. This compound is a potent muscarinic antagonist, with long duration of action in vivo, and was found to have a rapid hydrolysis in human plasma, minimizing the potential to induce class-related systemic side effects. Aclidinium bromide is currently in phase III development for maintenance treatment of patients with COPD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Inhalation
-
Animals
-
Bronchial Spasm / drug therapy
-
Bronchial Spasm / physiopathology
-
CHO Cells
-
Cricetinae
-
Cricetulus
-
Drug Stability
-
Esters
-
Guinea Pigs
-
Humans
-
Male
-
Mice
-
Muscarinic Antagonists / chemical synthesis*
-
Muscarinic Antagonists / chemistry
-
Muscarinic Antagonists / pharmacology
-
Pulmonary Disease, Chronic Obstructive / drug therapy
-
Quaternary Ammonium Compounds / chemical synthesis*
-
Quaternary Ammonium Compounds / chemistry
-
Quaternary Ammonium Compounds / pharmacology
-
Quinuclidines / chemical synthesis*
-
Quinuclidines / chemistry
-
Quinuclidines / pharmacology
-
Radioligand Assay
-
Receptor, Muscarinic M3 / physiology
-
Stereoisomerism
-
Structure-Activity Relationship
-
Tropanes / chemical synthesis*
-
Tropanes / chemistry
-
Tropanes / pharmacology
Substances
-
Esters
-
Muscarinic Antagonists
-
Quaternary Ammonium Compounds
-
Quinuclidines
-
Receptor, Muscarinic M3
-
Tropanes
-
aclidinium bromide